The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Identifying actionable targets in advanced cancer patients: Preliminary results from the Profiler program.
Philippe Cassier
Consultant or Advisory Role - SERVIER
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Novartis; Roche
Other Remuneration - Novartis
Olivier Trédan
No relevant relationships to disclose
Christelle Seigne
No relevant relationships to disclose
Emilie Lavergne
No relevant relationships to disclose
Jerome Fayette
No relevant relationships to disclose
Françoise Desseigne
No relevant relationships to disclose
Pierre Biron
No relevant relationships to disclose
Christelle De La Fouchardiere
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Consultant or Advisory Role - PharmaMar; Roche
Honoraria - PharmaMar; Roche
Maurice Pérol
Consultant or Advisory Role - Boehringer Ingelheim (U); Lilly; Pfizer; Roche/Genentech
Honoraria - Lilly; Pfizer; Roche/Genentech
Other Remuneration - Lilly; Roche/Genentech
Didier Frappaz
No relevant relationships to disclose
Mathilde Bernardin
No relevant relationships to disclose
Qing Wang
No relevant relationships to disclose
Valéry Attignon
No relevant relationships to disclose
Daniel Pissaloux
No relevant relationships to disclose
Valérie Combaret
No relevant relationships to disclose
Vincent Agrapart
No relevant relationships to disclose
Marie-Eve Fondrevelle
No relevant relationships to disclose
David Pérol
No relevant relationships to disclose
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Novartis; Roche
Research Funding - Bayer; GlaxoSmithKline; Novartis; Roche